S
Spyre Therapeutics, Inc. (SYRE)
NMS – Real Time Price. Currency in USD
75.04
-1.39 (-1.82%)
At close: May 12, 2026, 4:00 PM EDT
75.79
+0.75 (1.00%)
After-hours: May 12, 2026, 7:20 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
75.04
-1.39 (-1.82%)
At close: May 12, 2026, 4:00 PM EDT
75.79
+0.75 (1.00%)
After-hours: May 12, 2026, 7:20 PM EDT
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the α4β7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn’s disease); and SPY002 and SPY072 – anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-α4β7 and anti-TL1A mAbs; SPY130, a combination anti-α4β7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
| Name | Position |
|---|---|
| Dr. Cameron Turtle DPHIL, Ph.D. | CEO & Director |
| Dr. Janet Gunzner-Toste M.B.A., Ph.D. | Senior Vice President of Operations |
| Dr. Justin LaFountaine Ph.D. | Senior Vice President of Corporate Development |
| Dr. Sheldon Sloan M.B.E., M.D. | Chief Medical Officer |
| Mr. Brian Connolly | Chief Technical Officer |
| Mr. Eric McIntyre | Vice President of Finance & Investor Relations |
| Mr. James Myers | Vice President of Quality & Compliance |
| Mr. Scott L. Burrows | Chief Financial Officer |
| Ms. Heidy Abreu King-Jones J.D., L.L.M. | Chief Legal Officer & Corporate Secretary |
| Ms. Melissa Cooper | Senior Vice President of People |
| Date | Type | Document |
|---|---|---|
| 2026-05-05 | 8-K | syre-20260505.htm |
| 2026-04-16 | 8-K | syre-20260414.htm |
| 2026-04-13 | 8-K | syre-20260413.htm |
| 2026-04-10 | DEFA14A | a2026spyredefa14amaterials.htm |
| 2026-04-10 | DEF 14A | syre-20260410.htm |
| 2026-02-27 | POS AM | spyre-posamonsx3.htm |
| 2026-02-25 | CORRESP | filename1.htm |
| 2026-02-19 | S-8 | spyre-february2026xsx8.htm |
| 2026-02-19 | S-3 | spyre-sx3.htm |
| 2026-01-12 | 8-K | d28401d8k.htm |